

For Immediate Release
July 25, 2011

**SUNSHINE BIOPHARMA'S LEAD ANTI-TUMOR COMPOUND, Adva-27a, IS
CLEARED VIA A CYTOCHROME P450-INDEPENDENT MECHANISM**

Montreal, Quebec, Canada -- (*Canada Newswire*) -- Sunshine Biopharma Inc. (OTCBB: SBFM) a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a study in which the mechanism of clearance of the Company's new drug, Adva-27a, was analyzed using human liver microsomes in vitro. Clearance refers to the mechanism by which a drug is metabolized and eliminated by the body. One of the pathways for eliminating drugs by the body involves the Cytochrome P450 catalytic cycle. In drug development it is important to determine whether or not a given compound of interest undergoes elimination through the Cytochrome P450 catalytic cycle as this natural process can produce toxic (poisonous) intermediates which would render the compound unusable as a drug. Studies of this nature are initially performed in vitro using human liver microsomes containing or lacking Cytochrome P450 activity. The results of such studies for the Company's Adva-27a, revealed that this compound is cleared by pathways which are independent of Cytochrome P450. The observed intrinsic clearance rates (microliter per minute per milligram protein) for Adva-27a were 60 and 43 in the presence and absence of Cytochrome P450 activity, respectively.

"As a result of this study, Adva-27a meets yet another of the criteria of a good pharmaceutical drug", said Dr. Steve N. Slilaty, Sunshine's President and CEO. "In this type of study, the difference between 60 and 43 in terms of observed intrinsic clearance rate is not considered significant. Scientifically, these data are interpreted as Adva-27a undergoes Non-Cytochrome P450 mediated degradation", he added.

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For Additional Information Contact:

Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com